← 返回前沿论文

过继性 T 细胞联合放化疗对转移性前列腺癌细胞的协同获益

英文原题:Synergistic Benefit of Adoptive T Cells in Combination With Chemoradiotherapy Against Metastatic Prostate Cancer Cells.

PubMed 2022/07/01(内容时间) Anticancer Res Q4 · IF 1.8(JCR 2025)

研究概要

γδ T细胞疗法可能为PC治疗提供比传统放化疗更多的益处。

研究思路结论见上方概要

前列腺癌(PC)是影响男性健康的主要疾病之一,在全球男性最常见癌症中位居第二。尽管大多数新诊断的PC为高分化肿瘤,治愈概率较高,但仍有部分患者为侵袭性恶性肿瘤,具有复发和转移的潜能。细胞毒性T淋巴细胞是介导抗肿瘤免疫应答的特异性免疫效应细胞群。

在本研究中,通过Alamar blue细胞活力检测和细胞膜通透性检测,评估了外周血单个核细胞(PBMCs)来源的γδ T细胞和细胞因子诱导的杀伤(CIK)细胞联合放化疗对PC细胞的细胞毒性。

晚期PC-3细胞对多西他赛(Doc)更具耐药性,在放疗预处理后也表现出更高的活力。额外加入γδ T或CIK处理后,细胞增殖抑制显著增强。此外,与单独使用Doc或γδ T细胞治疗组相比,Doc-γδ T细胞联合治疗组的凋亡细胞比例显著增加(p<0.05)。

展开英文摘要原文

BACKGROUND/AIM: Prostate cancer (PC) is one of the major diseases that affects male health and ranks as the second most frequent cancer in men worldwide. Although most newly-diagnosed PCs are well-differentiated tumors with a high cure probability, there are some patients with aggressive malignancies that show potential for recurrence and metastasis. Cytotoxic T lymphocytes are a specific immune effector cell population that mediates immune responses against cancer. MATERIALS AND METHODS: In the present study, the cytotoxicity of peripheral blood mononuclear cells (PBMCs)-derived γδ T cells and cytokine-induced killer (CIK) cells in combination with chemoradiotherapy against PC cells was evaluated using Alamar blue cell viability and cell membrane permeability assays. RESULTS: Advanced PC-3 cells, which were more resistant to docetaxel (Doc), also showed higher viability following pretreatment with radiation. The cell proliferation inhibition was significantly increased upon additional γδ T or CIK treatment. Furthermore, the proportion of apoptotic cells was significantly (p<0.05) increased in the Doc-γδ T cell co-treatment group as compared with the Doc or γδ T cell treated alone group. CONCLUSION: γδ T cell therapy may provide additional benefit compared to traditional chemoradiotherapy for PC treatment.

论文信息

作者
Shen YC、Shih HJ、Lin CC、Huang SH、Wu SC、Hsiao CH、Chiu SC、Cho DY
第一作者单位
Division of Urology, Department of Surgery, Changhua Christian Hospital, Changhua, Taiwan, R.O.C.Taiwan
通讯作者单位
Translational Cell Therapy Center, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, R.O.C.; phs1O27@gmail.com.China
期刊
Anticancer research2022 Jul
原文标识
PubMed 35790265 · DOI 10.21873/anticanres.15829